Literature DB >> 19568348

Consensus statement and guidelines on the management of paragangliomas of the head and neck.

Mislav Gjuric1, Michael Gleeson.   

Abstract

Paragangliomas (PGLs) of the head and neck (H&N) are uncommon tumors that either arise spontaneously or as part of an inherited syndrome. Hereditary PGL is an autosomal-dominant tumor predisposition syndrome in which an affected individual has greatly increased risk of developing PGL at any or several sites in the autonomic nervous system. The mode of inheritance for some is affected by maternal imprinting. These tumors are generally very slow growing, often taking a decade to double in size. A few are or can become malignant and can metastasize widely. Because of their site of origin, patients with these tumors may develop cranial nerve deficits that have a significant impact on their quality of life. Patients may present to specialists from widely differing disciplines, and some of these may not appreciate the full implications of their patient's disease. As a result, management can become fragmented or inappropriate, and some aspects of care may even be overlooked. This article is the distillation of consensus opinion derived from current published and unpublished data in this field, with particular reference to the management of temporal bone PGLs. We propose guidelines for the management of both sporadic and hereditary PGLs. A multidisciplinary team approach to the management of this complex disorder is advocated. Progress could be made by adopting these guidelines and by widespread dissemination of standardized information. Collaborative research should be promoted with the aim of harnessing advances in molecular genetics to develop targeted therapies for patients, particularly those with hereditary PGL.

Entities:  

Keywords:  Head and neck paraganglioma; genetics; management; molecular biology; surgery

Year:  2009        PMID: 19568348      PMCID: PMC2637566          DOI: 10.1055/s-0028-1103131

Source DB:  PubMed          Journal:  Skull Base        ISSN: 1531-5010


  24 in total

1.  Combined endovascular-surgical management of the internal carotid artery in complex tympanojugular paragangliomas.

Authors:  Mario Sanna; Paolo Piazza; Giuseppe De Donato; Roberto Menozzi; Maurizio Falcioni
Journal:  Skull Base       Date:  2009-01

2.  Evolving concepts in the management of jugular paraganglioma: a comparison of radiotherapy and surgery in 88 cases.

Authors:  Patrice Tran Ba Huy; Romain Kania; Michèle Duet; Bernadette Dessard-Diana; Jean-Jacques Mazeron; Rania Benhamed
Journal:  Skull Base       Date:  2009-01

Review 3.  Rerouting of the intratemporal facial nerve: an analysis of the literature.

Authors:  S H Selesnick; M T Abraham; J F Carew
Journal:  Am J Otol       Date:  1996-09

4.  Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma.

Authors:  O Gimm; M Armanios; H Dziema; H P Neumann; C Eng
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

5.  Neural infiltration of glomus temporale tumors.

Authors:  M Makek; D J Franklin; J C Zhao; U Fisch
Journal:  Am J Otol       Date:  1990-01

6.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.

Authors:  Hartmut P H Neumann; Christian Pawlu; Mariola Peczkowska; Birke Bausch; Sarah R McWhinney; Mihaela Muresan; Mary Buchta; Gerlind Franke; Joachim Klisch; Thorsten A Bley; Stefan Hoegerle; Carsten C Boedeker; Giuseppe Opocher; Jörg Schipper; Andrzej Januszewicz; Charis Eng
Journal:  JAMA       Date:  2004-08-25       Impact factor: 56.272

7.  Management of jugular paragangliomas: the Gruppo Otologico experience.

Authors:  Mario Sanna; Yogesh Jain; Giuseppe De Donato; Lorenzo Lauda; Abdelkader Taibah
Journal:  Otol Neurotol       Date:  2004-09       Impact factor: 2.311

8.  Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.

Authors:  Anne-Paule Gimenez-Roqueplo; Judith Favier; Pierre Rustin; Claudine Rieubland; Malvina Crespin; Valérie Nau; Philippe Khau Van Kien; Pierre Corvol; Pierre-François Plouin; Xavier Jeunemaitre
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

9.  The juxtacondylar approach to the jugular foramen (without petrous bone drilling).

Authors:  B George; G Lot; P Tran Ba Huy
Journal:  Surg Neurol       Date:  1995-09

Review 10.  Screening for familial paragangliomas.

Authors:  David Myssiorek; Alfio Ferlito; Carl E Silver; Juan Pablo Rodrigo; Bora E Baysal; Johannes J Fagan; Carlos Suárez; Alessandra Rinaldo
Journal:  Oral Oncol       Date:  2007-11-01       Impact factor: 5.337

View more
  5 in total

1.  Stereotactic radiosurgery of glomus jugulare tumors: current concepts, recent advances and future perspectives.

Authors:  Omer Sager; Ferrat Dincoglan; Murat Beyzadeoglu
Journal:  CNS Oncol       Date:  2015

2.  Observation and partial targeted surgery in the management of tympano-jugular paraganglioma: a contribution to the multioptional treatment.

Authors:  Antonio Mazzoni; Elisabetta Zanoletti
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-31       Impact factor: 2.503

3.  CT cinematic rendering for glomus jugulare tumor with intracranial extension.

Authors:  Dario Baldi; Liberatore Tramontano; Bruna Punzo; Mario Orsini; Carlo Cavaliere
Journal:  Quant Imaging Med Surg       Date:  2020-02

4.  Surgical management of giant transdural glomus jugulare tumors with cerebellar and brainstem compression.

Authors:  Matthew L Carlson; Colin L W Driscoll; Joaquin J Garcia; Jeffrey R Janus; Michael J Link
Journal:  J Neurol Surg B Skull Base       Date:  2012-06

Review 5.  Acute and Chronic Pheochromocytoma-Induced Cardiomyopathies: Different Prognoses?: A Systematic Analytical Review.

Authors:  Marie Batisse-Lignier; Bruno Pereira; Pascal Motreff; Romain Pierrard; Christelle Burnot; Charles Vorilhon; Salwan Maqdasy; Béatrice Roche; Francoise Desbiez; Guillaume Clerfond; Bernard Citron; Jean-René Lusson; Igor Tauveron; Romain Eschalier
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.